Major Depressive Disorder

Showing NaN - NaN of 86

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multi-Omic, Clinomic and Digitomic Attributes of Major

Not yet recruiting
  • Major Depressive Disorder
  • Unipolar, Non-psychotic Major Depressive Disorder
    • Jacksonville, Florida
      Mayo Clinic Florida
    Jun 11, 2023

    MDD Trial in United States (REL-1017)

    Recruiting
    • Major Depressive Disorder
    • Saraland, Alabama
    • +102 more
    Jan 18, 2023

    MDD Trial in United States (SAGE-217, Placebo)

    Completed
    • Major Depressive Disorder
    • Rogers, Arkansas
    • +52 more
    Nov 22, 2022

    Depression, MDD Trial in Jacksonville, Rochester (Clinical decision support tool)

    Completed
    • Depression
    • Major Depressive Disorder
    • Clinical decision support tool
    • Jacksonville, Florida
    • +1 more
    Dec 9, 2022

    Migraine, MDD Trial in Worldwide (Fremanezumab, Placebo)

    Completed
    • Migraine
    • Major Depressive Disorder
    • Little Rock, Arkansas
    • +63 more
    Dec 7, 2022

    MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)

    Completed
    • Major Depressive Disorder
    • +2 more
    • AXS-05 (dextromethorphan and bupropion) oral tablets
    • Phoenix, Arizona
    • +50 more
    Sep 16, 2022

    MDD Trial in Australia, United States (10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114)

    Completed
    • Major Depressive Disorder
    • 10 mg PRAX-114
    • +4 more
    • Lafayette, California
    • +23 more
    Aug 18, 2022

    MDD Trial in Australia, United States (PRAX-114, Placebo)

    Completed
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +30 more
    Jul 20, 2022

    MDD Trial in United States (SP-624, Placebo)

    Active, not recruiting
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +38 more
    May 13, 2022

    MDD Trial in United States (REL-1017, Placebo)

    Recruiting
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +57 more
    May 9, 2022

    MDD Trial in United States (REL-1017, Placebo)

    Recruiting
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +52 more
    Apr 14, 2022

    MDD Trial in Worldwide (Lumateperone, Placebo)

    Recruiting
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +27 more
    Apr 7, 2022

    MDD Trial in Worldwide (Lumateperone)

    Enrolling by invitation
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +44 more
    Apr 7, 2022

    MDD Trial in United States (BTRX-335140, Placebo)

    Active, not recruiting
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +37 more
    Mar 11, 2022

    MDD Trial in United States (Levomilnacipran ER, Fluoxetine, Placebo)

    Completed
    • Major Depressive Disorder
    • Levomilnacipran ER
    • +2 more
    • Little Rock, Arkansas
    • +50 more
    Mar 1, 2022

    MDD Trial in United States (SAGE-217, Placebo)

    Terminated
    • Major Depressive Disorder
    • Bentonville, Arkansas
    • +45 more
    Oct 15, 2021

    Depression, MDD Trial in United States (AXS-05, Placebo)

    Completed
    • Depression
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +42 more
    Sep 22, 2021

    MDD Trial in United States (AXS-05, Bupropion)

    Completed
    • Major Depressive Disorder
    • Beverly Hills, California
    • +3 more
    Sep 22, 2021

    MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)

    Terminated
    • Major Depressive Disorder
    • SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
    • Birmingham, Alabama
    • +211 more
    Jun 9, 2021

    MDD Trial in Worldwide (Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine

    Completed
    • Major Depressive Disorder
    • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
    • +4 more
    • Little Rock, Arkansas
    • +81 more
    May 25, 2021

    MDD Trial in United States (BTRX-246040 oral capsule(s), Placebo oral capsule(s))

    Completed
    • Major Depressive Disorder
    • BTRX-246040 oral capsule(s)
    • Placebo oral capsule(s)
    • Cerritos, California
    • +7 more
    Apr 19, 2021

    MDD Trial in United States (CP-601,927, Placebo)

    Terminated
    • Major Depressive Disorder
    • Little Rock, Arkansas
    • +57 more
    Apr 7, 2021

    MDD Trial in Australia, Puerto Rico, United States (ALKS 5461, ALKS 5461 Placebo)

    Completed
    • Major Depressive Disorder
    • ALKS 5461
    • ALKS 5461 Placebo
    • Tucson, Arizona
    • +34 more
    Mar 15, 2021

    MDD Trial in United States (Vortioxetine, Placebo)

    Completed
    • Major Depressive Disorder
    • Phoenix, Arizona
    • +78 more
    Dec 16, 2020

    MDD Trial in Puerto Rico, United States (AGO178)

    Terminated
    • Major Depressive Disorder
    • Birmingham, Alabama
    • +97 more
    Dec 16, 2020